ANDA Dossier Preparation Services
CMC deficiencies are the leading reason ANDAs lose review cycles. We build Module 3 from the manufacturing floor up — batch records, stability, process validation — and back it with bioequivalence studies run at our own clinical facility.
Pathway — 505(j)
Native Strength
Methods
Review Goal
What Goes Into a US FDA ANDA?
An Abbreviated New Drug Application is the US FDA pathway for generic drugs under section 505(j). Instead of repeating the innovator’s clinical program, the applicant demonstrates that the generic has the same active ingredient, strength, dosage form, route, and labeling as the Reference Listed Drug — and proves bioequivalence to it. The dossier is filed in eCTD format, and its centre of gravity is Module 3: the chemistry, manufacturing, and controls evidence for the drug substance and drug product.
That is also where ANDAs fail. CMC deficiencies are the leading cause of complete response letters — stability programs that fall short of the three-batch requirement, analytical methods validated on paper but not defensible under review, process validation that does not match the batch records. Each deficiency cycle costs months against a GDUFA standard review goal of about ten months, and first-cycle approval belongs almost entirely to submission quality.
Celesta Healthcare approaches ANDAs from an unusual direction: we work with WHO-GMP manufacturing every day, so the batch records, stability protocols, and process validation reports that make up Module 3 are documents our team handles natively rather than requests from a checklist. And the bioequivalence evidence in Module 5 comes from our own clinical research facility — DCGI-mandated, ANVISA-approved, and designed for US FDA and EMA regulated markets.
The US FDA application for a generic drug under section 505(j). It relies on the agency’s prior findings for the reference product and proves sameness plus bioequivalence instead of repeating clinical efficacy trials.
The approved innovator product, listed in the FDA’s Orange Book, that a generic must match in active ingredient, strength, dosage form, route, and labeling — and against which bioequivalence is demonstrated.
ANDA vs NDA — Two Routes to the US Market
The generic pathway trades clinical trials for bioequivalence — which moves the burden of proof onto CMC and BE quality.
| Aspect | ANDA — 505(j) | NDA — 505(b)(1) |
|---|---|---|
| Purpose | Approval of a generic version of a listed drug | Approval of a new drug on its own evidence |
| Clinical evidence | Bioequivalence to the RLD — no new efficacy trials | Full Phase I–III safety and efficacy program |
| Key acceptance test | 90% CI of Cmax & AUC ratios within 80.00–125.00% | Clinical endpoints demonstrating benefit and safety |
| Dossier centre of gravity | Module 3 (CMC) and BE study reports | Module 5 clinical data across the program |
| Review goal | About 10 months standard under GDUFA III | About 10–12 months under PDUFA goals |
| Cost & timeline | A fraction of NDA cost; BE studies in weeks | Years of development and clinical spend |
ANDA Services Across the Dossier
Module 3 CMC Compilation
Drug substance and drug product sections built from batch records, specifications, and validation data we know how to read.
Bioequivalence Studies In-House
Fasting and fed BE studies at our own clinical facility, with LC-MS/MS bioanalysis feeding Module 5 directly.
Stability Program Guidance
Three-batch stability strategy planned to FDA expectations — accelerated and long-term data ready at submission.
Pre-Submission Gap & RTR Check
The application audited against refuse-to-receive criteria so the ANDA is substantially complete on day one.
eCTD Publishing to US FDA
Publishing, technical validation, and submission through the FDA gateway, with lifecycle sequences thereafter.
CRL & Information Request Responses
Deficiency responses drafted with the manufacturing and clinical teams, not relayed through intermediaries.
Module 3 Built From the Factory Floor
Pure regulatory consultants request CMC documents; we work with them. Daily exposure to WHO-GMP manufacturing means batch manufacturing records, process validation, and stability protocols are our working language — which shows in dossiers that are faster to compile and harder to question. On the clinical side, bioequivalence studies run at our DCGI-mandated, ANVISA-approved facility designed for US FDA and EMA regulated markets, on coupled AB Sciex LC-MS/MS units against 75+ validated methods. Modules 3 and 5, both from primary sources.
Why Sponsors Choose Us for ANDA Dossiers
- Manufacturing-side fluency in batch records, stability, and process validation
- BE studies at our own DCGI-mandated, ANVISA-approved clinical facility
- Facility designed for US FDA and EMA regulated markets
- Refuse-to-receive audit before every submission
- eCTD publishing and validation handled in-house
- One accountable team from gap analysis to approval
ANDA Dossiers — Frequently Asked Questions
1. What is an ANDA?
2. What is the difference between an ANDA and an NDA?
3. Do ANDA submissions require clinical trials?
4. How long does ANDA approval take?
5. What stability data does an ANDA require?
6. What is a refuse-to-receive (RTR)?
7. What is a Paragraph IV certification?
More Regulatory Affairs Services
Every study type under one roof — explore the rest of our regulatory affairs capabilities.
Dossier Preparation
Module 1–5 compilation, gap analysis, and eCTD publishing — submission-ready for every target agency.
DCGI & CDSCO Approvals
Clinical trial applications, BE-NOCs, test licences, and new drug approvals under the NDCT Rules, 2019.
ANVISA / Brazil
BE studies at our ANVISA-approved centre plus CTD dossiers and query management for Brazil.
Discuss Your ANDA Dossiers Requirement
Share your molecule and target market — our scientific team responds with a study design, timeline, and detailed proposal within 24 business hours.